Segal, Neil Howard
Mayo Clinic
Memorial Sloan Kettering Cancer Center
Citations 2
Safety and efficacy of durvalumab (MEDI4736), a PD-L1 antibody, in urothelial bladder cancer.
Massard, Christophe, Sharma, Sunil, Rafii, Saeed , Colón‐Otero, Gerardo , Hamid, Omid , O’Donnell, Peter H. , Drakaki, Alexandra , Kurland, John F. , Rebelatto, Marlon C., Jin, Xiaoping , Blake-Haskins, John A., Gupta, Ashok , Rafii, Saeed , Gordon, Michael S. , Wainberg, Zev A. , Luke, Jason J. , Curiel, Tyler Jay , Sanborn, Rachel E , Drakaki, Alexandra , Segal, Neil Howard
Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 4502-4502
Safety and clinical activity of durvalumab in combination with tremelimumab in extensive disease small-cell lung cancer (ED-SCLC).
Cho, Daniel C. , Dowlati, Afshin , Chung, Ki Y. , Schneider, Bryan J. , Razak, Albiruni Ryan Abdul, Tsai, Frank , Balmanoukian, Ani Sarkis, Xiao, Feng , Angra, Natasha, Abdullah, Shaad E. , Mahipal, Amit , Chow, Warren , Segal, Neil Howard , Nemunaitis, John , Bazhenova, Lyudmila , Luke, Jason J.
Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 8517-8517